Achillion Pharmaceuticals (Achillion Pharmaceuticals) EPS (Basic) : $-0.54 (TTM As of Sep. 2019)

View and export this data going back to 2006. Start your Free Trial

What is Achillion Pharmaceuticals EPS (Basic)?

Achillion Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2019 was $-0.14. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2019 was $-0.54.

Achillion Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2019 was $-0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-0.54.

Achillion Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2019 was $-0.14. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2019 was -0.54.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Achillion Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Achillion Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achillion Pharmaceuticals EPS (Basic) Chart

Achillion Pharmaceuticals Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

EPS (Basic)

Get a 7-Day Free Trial

-0.70

-0.04

-0.45

-0.62

-0.51

Achillion Pharmaceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EPS (Basic)	Get a 7-Day Free Trial															-0.12	-0.12	-0.14	-0.14	-0.14

Achillion Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Achillion Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2018 is calculated as

Basic EPS (A: Dec. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-70.272	-	0)	/	138.418
	=	-0.51

Achillion Pharmaceuticals's Basic EPS for the quarter that ended in Sep. 2019 is calculated as

Basic EPS (Q: Sep. 2019 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-19.583	-	0)	/	139.589
	=	-0.14

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.54

Achillion Pharmaceuticals (NAS:ACHN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Achillion Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Achillion Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achillion Pharmaceuticals Inc (NAS:ACHN) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 George Street, New Haven, CT, USA, 06511

Website

http://www.achillion.com

Achillion Pharmaceuticals Inc is a biotechnology company that seeks to discover and commercialize treatments for rare diseases. The company is engaged solely in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders. Achillion specializes in structural biology, medicinal chemistry, and antimicrobial discovery research. The company generates revenue from product sales, regulatory and commercialization milestones, and royalties. Achillion also uses collaborative and licensing agreements.

Executives

Joseph Truitt	director, officer: Chief Executive Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Kurt Graves	director	C/O ACHILLION PHARMACEUTICALS INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael D Kishbauch	director	18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Jason S Fisherman	director	C/O ADVENT INTERNATIONAL CORP, 75 STATE ST 29TH FLOOR, BOSTON MA 02104
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Nicole Vitullo	director	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Martha E Manning	officer: General Counsel	700 PENNSYLVANIA DR, EXTON PA 19341
Frank Verwiel	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Paul E Firuta	officer: EVP, Chief Commercial Officer	550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER NJ 07921
Steven Zelenkofske	officer: EVP, Chief Medical Officer	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Mary Kay Fenton	officer: Chief Financial Officer	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Milind Deshpande	director, officer: Chief Executive Officer	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
David Apelian	officer: Chief Medical Officer	C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511